Stockreport

ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022)

ADC Therapeutics SA Common Shares  (ADCT) 
PDF Initial safety run-in results from LOTIS-5 Phase 3 trial demonstrate ORR of 75% and 40% CR rate with no new safety signalsCami pivotal Phase 2 data to be highlighted in [Read more]